litlas
Log inCreate account

Robert P. Giugliano

Active 1984–2026

Also published as
Robert P Giugliano
223
Papers
55,781
Citations
106
h-index
215
i10-index

Citations

Citations per year for Robert P. Giugliano1969: 4 citations1970: 1 citations1985: 4 citations1986: 1 citations1989: 2 citations1990: 2 citations1991: 2 citations1992: 1 citations1993: 3 citations1994: 3 citations1995: 1 citations1998: 4 citations1999: 9 citations2000: 28 citations2001: 54 citations2002: 32 citations2003: 58 citations2004: 94 citations2005: 96 citations2006: 67 citations2007: 80 citations2008: 63 citations2009: 60 citations2010: 67 citations2011: 85 citations2012: 88 citations2013: 134 citations2014: 191 citations2015: 332 citations2016: 485 citations2017: 660 citations2018: 652 citations2019: 2,189 citations2020: 2,093 citations2021: 1,926 citations2022: 1,726 citations2023: 1,360 citations2024: 2,390 citations2025: 1,219 citations2026: 110 citations1971–1984: no citations, so these years are not shown1987–1988: no citations, so these years are not shown1996–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,195 citing papers, 19.6% of this breakdownUnited Kingdom: 1,761 citing papers, 8.2% of this breakdownItaly: 1,256 citing papers, 5.9% of this breakdownChina: 1,220 citing papers, 5.7% of this breakdownGermany: 1,191 citing papers, 5.6% of this breakdownCanada: 1,126 citing papers, 5.3% of this breakdownNetherlands: 809 citing papers, 3.8% of this breakdownFrance: 726 citing papers, 3.4% of this breakdownAustralia: 700 citing papers, 3.3% of this breakdownSpain: 585 citing papers, 2.7% of this breakdownDenmark: 566 citing papers, 2.7% of this breakdownJapan: 538 citing papers, 2.5% of this breakdown
0%19.6%Other 31.3%

Institutions

Fields

  • Medicine84.6%
  • Biochemistry, Genetics and Molecular Biology7.9%
  • Immunology and Microbiology2.2%
  • Nursing1.4%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Computer Science0.5%
  • Other2.7%

Topics

  • Lipoproteins and Cardiovascular Health10.7%
  • Atrial Fibrillation Management and Outcomes7.8%
  • Diabetes, Cardiovascular Risks, and Lipoproteins4.5%
  • Acute Myocardial Infarction Research3.4%
  • Venous Thromboembolism Diagnosis and Management3.2%
  • Antiplatelet Therapy and Cardiovascular Diseases3%
  • Other67.4%

Coauthors

All papers

Open in search
  1. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

    Authors: Marc S. Sabatine, Robert P. Giugliano, Anthony Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia Kuder, Huei Wang, Thomas Liu, Scott M. Wasserman, Peter Sever, Terje R. Pedersen - New England Journal of Medicine 2017 cited by 5,987

  2. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

    Authors: Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano, Amy McCagg, Jennifer A. White, Pierre Théroux, Harald Darius, Basil S. Lewis, Ton Oude Ophuis, J. Wouter Jukema, Gaetano Maria De Ferrari, Witold Rużyłło, Paul De Lucca, KyungAh Im, Erin A. Bohula, Craig Reist, Stephen D. Wiviott, Andrew M. Tershakovec, Thomas A. Musliner, Eugene Braunwald, Robert M. Califf - New England Journal of Medicine 2015 cited by 4,415

  3. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

    Authors: Christian T. Ruff, Robert P. Giugliano, Eugene Braunwald, Elaine Hoffman, Naveen Deenadayalu, Michael D. Ezekowitz, A. John Camm, Jeffrey I. Weitz, Basil S. Lewis, Alexander Parkhomenko, Takeshi Yamashita, Elliott M. Antman - The Lancet 2013 cited by 4,971

  4. Edoxaban versus Warfarin in Patients with Atrial Fibrillation

    Authors: Robert P. Giugliano, Christian T. Ruff, Eugene Braunwald, Sabina A. Murphy, Stephen D. Wiviott, Jonathan L. Halperin, Albert L. Waldo, Michael Ezekowitz, Jeffrey I. Weitz, Jindřich Špinar, Witold Rużyłło, Mikhail Ruda, Yukihiro Koretsune, Joshua Betcher, Minggao Shi, Laura T. Grip, Shirali P. Patel, Indravadan Patel, James Hanyok, Michele Mercuri, Elliott M. Antman - New England Journal of Medicine 2013 cited by 5,126

  5. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

    Authors: Michael G. Silverman, Brian A. Ference, Kyungah Im, Stephen D. Wiviott, Robert P. Giugliano, Scott M. Grundy, Eugene Braunwald, Marc S. Sabatine - JAMA 2016 cited by 1,473

  6. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

    Authors: Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano, Erik S.G. Stroes, Estella Kanevsky, Ioanna Gouni‐Berthold, KyungAh Im, Armando Lira Pineda, Scott M. Wasserman, R Češka, М. В. Ежов, J. Wouter Jukema, Henrik Kjærulf Jensen, S. Lale Tokgözoğlu, François Mach, Kurt Huber, Peter Sever, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine - Circulation 2019 cited by 948

  7. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

    Authors: Michelle L. O’Donoghue, Robert P. Giugliano, Stephen D. Wiviott, Dan Atar, Anthony Keech, Julia Kuder, KyungAh Im, Sabina A. Murphy, Jose H. Flores‐Arredondo, J. Antonio G. López, Mary Elliott‐Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Marc S. Sabatine - Circulation 2022 cited by 380

  8. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

    Authors: Brian A. Bergmark, Nicholas Marston, Thomas A Prohaska, Veronica Alexander, André Zimerman, Filipe A. Moura, Sabina A. Murphy, Erica L. Goodrich, S. M. Zhang, Daniel Gaudet, Ewa Karwatowska‐Prokopczuk, Sotirios Tsimikas, Robert P. Giugliano, Marc S. Sabatine - New England Journal of Medicine 2024 cited by 182

  9. Acute coronary syndromes

    Authors: Brian A Bergmark, Njambi Mathenge, Piera A Merlini, Marilyn B Lawrence-Wright, Robert P Giugliano - The Lancet 2022 cited by 427

  10. Lipoprotein(a) and its Significance in Cardiovascular Disease

    Authors: Freddy Duarte Lau, Robert P. Giugliano - JAMA Cardiology 2022 cited by 366

  11. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

    Authors: Anthony P. Carnicelli, Hwanhee Hong, Stuart J. Connolly, John Eikelboom, Robert P. Giugliano, David A. Morrow, Manesh R. Patel, Lars Wallentin, John H. Alexander, M. Cecilia Bahit, Alexander P. Benz, Erin A. Bohula, Tze-Fan Chao, Leanne Dyal, Michael Ezekowitz, Keith A.A. Fox, Baris Gencer, Jonathan L. Halperin, Ziad Hijazi, Stefan H. Hohnloser, Kaiyuan Hua, Elaine Hylek, Eri Toda Kato, Julia Kuder, Renato D. Lopes, Kenneth W. Mahaffey, Jonas Oldgren, Jonathan P. Piccini, Christian T. Ruff, Jan Steffel, Daniel Wojdyla, Christopher B. Granger - Circulation 2022 cited by 369

  12. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis

    Authors: Nicholas Marston, Robert P. Giugliano, Giorgio Melloni, Jeong‐Gun Park, Valerie N. Morrill, Michael A. Blazing, Brian A. Ference, Evan A. Stein, Erik S.G. Stroes, Eugene Braunwald, Patrick T. Ellinor, Steven A. Lubitz, Christian T. Ruff, Marc S. Sabatine - JAMA Cardiology 2021 cited by 266

  13. Variation inPCSK9andHMGCRand Risk of Cardiovascular Disease and Diabetes

    Authors: Brian A. Ference, Jennifer G. Robinson, Robert D. Brook, Alberico L. Catapano, M. John Chapman, David Neff, Szilárd Vörös, Robert P. Giugliano, George Davey Smith, Sergio Fazio, Marc S. Sabatine - New England Journal of Medicine 2016 cited by 784

  14. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

    Authors: Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park, Gaetano Maria De Ferrari, Zbigniew Gaciong, R Češka, Kálmán Tóth, Ioanna Gouni‐Berthold, José López‐Miranda, François Schiele, François Mach, Brian R. Ott, Estella Kanevsky, Armando Lira Pineda, Ransi Somaratne, Scott M. Wasserman, Anthony Keech, Peter S. Sever, Marc S. Sabatine - The Lancet 2017 cited by 677

  15. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

    Authors: Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony Keech, Armando Lira Pineda, Estella Kanevsky, Julia Kuder, Sabina A. Murphy, J. Wouter Jukema, Basil S. Lewis, Lâle Tokgözoğlu, Ransi Somaratne, Peter Sever, Terje R. Pedersen, Marc S. Sabatine - Circulation 2017 cited by 754

  16. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    Authors: Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, Frederick J. Raal, Dirk Blom, Jennifer G. Robinson, Christie M. Ballantyne, Ransi Somaratne, Jason C. Legg, Scott M. Wasserman, Robert C. Scott, Michael J. Koren, Evan A. Stein - New England Journal of Medicine 2015 cited by 1,495

  17. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

    Authors: Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott, Robert P. Giugliano, Prakash Deedwania, Gaetano Maria De Ferrari, Sabina A. Murphy, Julia Kuder, Ioanna Gouni‐Berthold, Basil S. Lewis, Yehuda Handelsman, Armando Lira Pineda, Narimon Honarpour, Anthony Keech, Peter S. Sever, Terje R. Pedersen - The Lancet Diabetes & Endocrinology 2017 cited by 596

  18. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes

    Authors: Nicholas Marston, Robert P. Giugliano, KyungAh Im, Michael G. Silverman, Michelle L. O’Donoghue, Stephen D. Wiviott, Brian A. Ference, Marc S. Sabatine - Circulation 2019 cited by 301

  19. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation

    Authors: David A. Morrow, Elliott M. Antman, Andrew Charlesworth, Richard Cairns, Sabina A. Murphy, James A. de Lemos, Robert P. Giugliano, Carolyn H. McCabe, Eugene Braunwald - Circulation 2000 cited by 1,575

  20. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE

    Authors: Prakriti Gaba, Michelle L. O’Donoghue, Jeong‐Gun Park, Stephen D. Wiviott, Dan Atar, Julia Kuder, KyungAh Im, Sabina A. Murphy, Gaetano Maria De Ferrari, Zbigniew Gaciong, Kálmán Tóth, Ioanna Gouni‐Berthold, José López‐Miranda, François Schiele, François Mach, Jose H. Flores‐Arredondo, J. Antonio G. López, Mary Elliott‐Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Robert P. Giugliano, Marc S. Sabatine - Circulation 2023 cited by 173

  21. Cognitive Function in a Randomized Trial of Evolocumab

    Authors: Robert P. Giugliano, François Mach, Kenton H. Zavitz, Christopher E. Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine, Peter S. Sever, Jennifer G. Robinson, Narimon Honarpour, Scott M. Wasserman, Brian R. Ott - New England Journal of Medicine 2017 cited by 482

  22. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials

    Authors: Bariş Gencer, Nicholas Marston, KyungAh Im, Christopher P. Cannon, Peter Sever, Anthony Keech, Eugene Braunwald, Robert P. Giugliano, Marc S. Sabatine - The Lancet 2020 cited by 314

  23. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

    Authors: Robert P. Giugliano, Terje R. Pedersen, Jeffrey L. Saver, Peter S. Sever, Anthony Keech, Erin A. Bohula, Sabina A. Murphy, Scott M. Wasserman, Narimon Honarpour, Huei Wang, Armando Lira Pineda, Marc S. Sabatine, on behalf of the FOURIER Investigators - Stroke 2020 cited by 182

  24. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis

    Authors: Eri Kato, David A. Morrow, Jianping Guo, David D. Berg, Michael A. Blazing, Erin A. Bohula, Marc P. Bonaca, Christopher P. Cannon, James A. de Lemos, Robert P. Giugliano, Petr Jarolı́m, Tibor Kempf, L. Kristin Newby, Michelle L. O’Donoghue, Marc A. Pfeffer, Nader Rifai, Stephen D. Wiviott, Kai C. Wollert, Eugene Braunwald, Marc S. Sabatine - European Heart Journal 2022 cited by 98